Insmed
INSM
#560
Rank
$41.38 B
Marketcap
$194.06
Share price
-1.27%
Change (1 day)
166.67%
Change (1 year)

P/E ratio for Insmed (INSM)

P/E ratio as of December 2025 (TTM): -31.5

According to Insmed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -31.454. At the end of 2024 the company had a P/E ratio of -12.4.

P/E ratio history for Insmed from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-12.4
2022-5.12-27.22%
2021-7.04-36.36%
2020-11.140.79%
2019-7.86152.66%
2018-3.11-71.48%
2017-10.9134.03%
2016-4.66-47.9%
2015-8.946.92%
2014-8.36

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Sarepta Therapeutics
SRPT
-8.15-74.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
17.9-157.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Gilead Sciences
GILD
18.3-158.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Array Technologies
ARRY
-13.8-56.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
-20.3-35.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Vertex Pharmaceuticals
VRTX
30.8-197.92%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.